JAK2 and acute lymphoblastic leukemia: Therapeutically important, JAK2 mutant-CRLF2–mediated and CRLF2 mutant–mediated transformation are sensitive to JAK inhibition in vitro, suggesting that ALL patients with CRLF2 overexpression may benefit from future kinase inhibitor approaches [41].